Journal article
Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration
Lisa M Aside, Brian A Darlow, Neil Finer, Barbara Schmidt, Ben Stenson, William Tarnow-Mordi, Peter G Davis, Waldemar A Carlo, Peter Brocklehurst, Lucy C Davies, Abhik Das, Wade Rich, Marie G Gantz, Robin S Roberts, Robin K Whyte, Lorrie Costantini, Christian Poets, Elizabeth Asztalos, Malcolm Battin, Henry L Halliday Show all
JAMA | AMER MEDICAL ASSOC | Published : 2018
Grants
Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services
Awarded by NHMRC
Awarded by National Institutes of Health
Awarded by National Heart, Lung, and Blood InstituteNational Institutes of Health
Awarded by Canadian Institutes of Health Research
Awarded by New Zealand Health Research Council
Awarded by Australian NHMRC
Awarded by EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
Awarded by EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES
Funding Acknowledgements
The data analysis was supported by grant RO3HD 079867 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services. Support for staff of the National Health and Medical Research Council (NHMRC) Clinical Trials Centre (University of Sydney, Sydney, Australia) was partly funded by NHMRC program grant 1037786. Dr Marlow receives funding from the UK Department of Health's National Institute for Health Research Biomedical Research Centre's funding scheme at University College London Hospital and the University College London. The SUPPORT trial was supported by grants from the Eunice Kennedy Shrivel-National Institute of Child Health and Human Development, and the National Heart, Lung, and Blood Institute, and from the National Institutes of Health (U10 HD21364, U10 HD21373, U10 HD21385, U10 HD21397, U10 HD27851, U10 HD27853, U10 HD27856, U10 HD27880, U10 HD27871, U10 HD27904, U10 HD34216, U10 HD36790, U10 HD40461, U10 HD40492, U10 HD40498, U10 HD40521, U10 HD40689, U10 HD53089, U10 HD53109, U10 HD53119, and U10 HD53124); and by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, cofunding from the National Heart, Lung, and Blood Institute, and grants from the National Institutes of Health (MO1 RR30, MO1 RR32, MO1 RR39, MO1 RR44, MO1 RR54, MO1 RR59, MO1 RR64, MO1 RR70, MO1 RR80, MO1 RR125, MO1 RR633, MO1 RR750, MO1 RR997, MO1 RR6022, MO1 RR7122, MO1 RR8084, MO1 RR16587, UL1 RR25008, UL1 RR24139, UL1 RR24979, and UL1 RR25744). The Canadian Oxygen Trial was funded by the Canadian Institutes of Health Research (MCT-79217). The BOOST New Zealand trial was funded by th New Zealand Health Research Council (05/145) and the Child Health Research Foundation. The BOOST II UK trial was funded by the UK Medical Research Council and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. The BOOST II Australia trial was supported by Australian NHMRC project grant 352386.